Com venda de Mounjaro, anúncios irregulares de medicamentos superam os de bets em 2025

Advertising watchdog Conar has released data indicating that irregular pharmaceutical and cosmetic promotions now represent a larger share of advertising complaints than sports betting violations in 2025. The shift reflects growing regulatory scrutiny around medication marketing, particularly as products like Mounjaro gain prominence in consumer awareness and direct-to-consumer advertising channels.

The 16.9% share attributed to pharmaceutical and cosmetic violations underscores mounting pressure on advertisers to comply with healthcare marketing standards. These rules typically govern claims about efficacy, safety disclosures, and the targeting of vulnerable populations. The rise in complaints may signal either increased enforcement activity or a genuine uptick in non-compliant campaigns as the market expands.

While sports betting advertising has dominated regulatory discussions in recent years—drawing criticism for aggressive promotion and targeting concerns—the pharmaceutical sector's emergence as a compliance challenge reflects broader industry maturation. As iGaming operators face tighter restrictions on their own marketing practices, the advertising landscape is becoming more complex across multiple verticals, with each sector navigating distinct regulatory frameworks and consumer protection mandates.